In this paper we propose a general joint model for longitudinal measurements and competing risks survival data. The model consists of a linear mixed effects sub-model for the longitudinal outcome, a proportional cause-specific hazards frailty sub-model for the competing risks survival data, and a regression sub-model for the variance-covariance matrix of the multivariate latent random effects based on a modified Cholesky decomposition. The model provides a useful approach to adjust for non-ignorable missing data due to dropout for the longitudinal outcome, enables analysis of the survival outcome with informative censoring and intermittently measured time-dependent covariates, as well as joint analysis of the longitudinal and survival outcomes. It also allows for high-dimensional heterogeneous covariance matrices of the multivariate random effects and the resulting estimated covariance matrices are guaranteed to be positive definite. A Bayesian MCMC procedure is developed for parameter estimation and inference. Its performances and frequentist properties are investigated using simulations. A real data example is used to illustrate the usefulness of the approach.
Introduction
Joint modeling of longitudinal and survival data has received a great deal of attention in the past decades in many studies in which both a longitudinal outcome during follow-up and the occurrence of some key events are recorded. In the statistical literature, joint models have been proposed to adjust inferences on longitudinal measurements in the presence of non-ignorable missing values due to dropout (31; 9; 24; 21; 20; 11; 12) ; to solve difficulties in Cox proportional hazards model arising from time-dependent covariates which are possibly missing at some event times or subject to substantial measurement error (14; 37; 13; 36; 38; 32; 1; 35; 40) ; and to assess covariates effects on both endpoints simultaneously (20; 41; 11; 12; 25) .
All the aforementioned joint models assume that the random effects covariance matrix is the same for all subjects. However, examining whether this matrix is the same for all subjects (homogeneous) or whether it differs depending on subject-specific characteristics (heterogeneous) is often neglected in the modeling. Furthermore, ignoring the heterogeneity can result in biased estimates of the fixed and random effects for the longitudinal outcome (19; 7) . Accounting for heterogeneity in covariance matrices has been discussed by serval authors in the field of generalized linear regression models (5), non-linear mixed models (8) , and linear mixed models (29; 23; 42; 7) . Nonetheless, no work has been done on modeling the entire random effects covariance matrix for the joint models.
In this paper, we propose an approach that allows heterogeneous random effects covariance matrix within the framework of joint analysis of longitudinal measurements and competing risks failure time data. In our joint model, a linear mixed effects sub-model is used to characterize the longitudinal measurements, a cause-specific hazards frailty sub-model for the competing risks survival data (30) , together with a regression sub-model for the joint multivariate random effects covariance matrix which links the first two sub-models. Specifically, we first use a modified Cholesky decomposition to decompose the covariance matrix into a lower-triangular matrix and a diagonal matrix, and then model these matrix entries using regression models (27; 7) . As discussed in the end of Section 2, our model includes homogeneous models as special cases. With different choices of regression covariates, it provides a flexible means to model the heterogeneity and reduce the number of variancecovariance parameters to be estimated. Moreover, the resulting estimated covariance matrices of the multivariate random effects are guaranteed to be positive definite. Likelihood-based inference for our model is rather challenging with high-dimensional random effects. We develop a Bayesian MCMC algorithm to fit the joint model. Gibbs sampling technique, together with Metropolis-Hastings sampling and adaptive rejection sampling methods, is used to draw random samples from the full conditional distribution of parameters. With the Bayesian approach, prior information can be incorporated in a natural way. If no prior information is available, we recommend noninformative priors for parameters to allow data to dominate the determination of the posterior distributions. This paper is organized as follows: in Section 2 we describe the joint model formulation. In Section 3 we develop the Bayesian estimation and inference methods. In Section 4, a real data application is illustrated using the data from the Scleroderma clinical trial (34) . In Section 5, the performance of our method is examined by simulation studies. Some concluding remarks are provided in Section 6. Details of the MCMC algorithm are deferred to the Appendix.
Joint Model
Our joint model consists of three components: a linear mixed effect model for the longitudinal measurements, a cause-specific hazards model for the competing risks survival data, and a regression model for the variance-covariance matrix of the multivariate latent random effects based on a modified Cholesky decomposition.
Longitudinal sub-model
Suppose there are m subjects in the study. For the ith subject at time t, the longitudinal outcome Y i (t) follows a linear mixed effects model:
where X (1) i (t) and Z i (t) are vectors of covariates associated with the fixed effects β (p×1) and the random effects U i (q×1) respectively. We assume that the measurement error i (t), which is distributed as N (0, σ 2 ), is independent of U i and i (t 1 ) ⊥ i (t 2 ) for any t 1 = t 2 .
Cause-specific hazards sub-model
During follow-up, each subject may experience one of g distinct competing causes of failure or may be right censored. Let C i = (T i , D i ) be the competing risks survival data on subject i, where T i is the failure or censoring time, and D i assumes a value from 0, 1, ..., g, with D i = 0 indicating a noninformative censored event and D i = k indicating the k th failure type, k = 1, ..., g. Dependent (or informative) censoring is treated as one of the g types of failures. The cause-specific hazards sub-model for the competing risks survival data is specified as follows:
The function λ k (t; X (2) i , v i , ν k , γ k ) is the instantaneous failure rate from cause k at time t given the vector of covariates X (2) i (t) and the latent unknown factor v i , in the presence of all other failure types. The regression coefficient ν k represents the effect of the latent variable v i with ν 1 set to 1 to ensure identifiability. The parameter γ k represents the effects of the observed covariates X (2) i (t) on cause k. We further assume that the k th baseline hazard is a step function, λ 0k (t) = λ 
Variance-covariance regression sub-model
We model the association between the longitudinal and survival sub-models by assuming that U i and v i jointly have a multivariate normal distribution:
Similar to (27) , we model the covariance matrices Σ i through a modified 
The diagonal entries of H i are the innovation variances (IV) h 
log h
where a i,jl and b ij are covariates, and η 1 and η 2 are low-dimensional parameter vectors. For example, a i,jl and b ij may contain group indicators, implying that the random effects covariances are heterogeneous. The homogeneous random effects assumption in existing joint models becomes a testable assumption within our model framework. Furthermore, the resulting estimated covariance matrix is guaranteed to be positive definite. The latent association between the longitudinal measurements and survival outcomes can be assessed by testing the hypothesis Σ U v i = 0. Finally, we assume that conditional on all the covariates and random effects, the longitudinal measurements and the competing risks survival data are independent.
Remark: Choice of design vectors for GARP/IV parameters. As we mentioned earlier, the choice of covariate vectors a i,jl and b i,j are flexible. For example, a 3-dimensional random effects variance-covariance matrix has 6 parameters. We can model the homogeneous unstructured covariance matrix by setting a i,jl = b ij = 1 for all j = 1, . . . , 3, l = 1, . . . , j −1. If we assume the design vectors contain subject-dependent covariate, say, a group indicator (G), the unstructured heterogeneous covariance matrix can be modeled
When there are high-dimensional random effects with limited data, one can impose a restricted covariance structure and assume some of the GARP parameters are the same to reduce the number of parameters.
Estimation and Inference
The standard maximum likelihood method involves integrating out latent variables from the log-likelihood function which is difficult when dealing with high-dimensional variables. We develop a Bayesian estimation procedure and a Markov chain Monte Carlo (MCMC) method for estimation and inference.
Likelihood
Suppose the longitudinal outcome Y i (t) is observed at time points t ij for j = 1, . . . , n i , and denote
. It is convenient to work directly with the joint distribution of the observed data (Y, C) and the unobservable random effects W , conditional on Ω, which facilitates the MCMC implementation. The conditional joint density of (Y, C) and W is:
where
and
Under the piecewise constant hazard assumption,
Priors and MCMC sampling procedure
We assume independent priors for Ω. We use Normal priors for the parameters β, γ, ν, η 1 and η 2 , leading to conjugate posteriors for β and some components of the η 1 . We use an inverse Gamma prior for the measurement error variance σ 
Application
We analyze the data from a scleroderma lung study (SLS) (34) with our proposed joint model. The study enrolled 158 patients with scleroderma-related interstitial lung disease, randomized to receive either CYC (79 patients) or identical appearing placebo (79 patients) for 12 months. An additional year of follow-up was performed to determine if CYC effects persisted after treatment. The primary outcome is forced vital capacity (FVC, % predicted), measured at 3-month intervals from the baseline. We are interested in evaluating if oral cyclophosphamide (CYC) can either improve the %FVC level of a patient or decrease the risk of treatment failure or death.
Since the full dose of CYC is not reached until month 6, our analysis is based on 6 − 24 months %FVC scores which includes 140 subjects. We observe 14 treatment failures or deaths, 32 informative and 5 noninformative dropouts. A dropout is noninformative if there is no evidence showing that the dropout is related to the disease or the treatment, and informative otherwise. Since the informative dropout is related to the patient's disease condition, it not only causes non-ignorable missing data in %FVC, but also is an informatively censored event for treatment failure or death.
We consider two baseline factors in our joint model when assessing the CYC treatment effects: baseline %FVC (F V C 0 ), and lung fibrosis (F IB 0 ). It is suggested by clinicians that the beneficial effects of CYC on pulmonary function continue to increase after stopping treatment at 12 months and eventually begin to waned after 18 months. Therefore, we fit the following linear spline mixed effects model with change point at month 18 for longitudinal measurements %FVC:
where U i is the subject-specific random effect and the ij is the mutually independent measurement error. We consider multiple choices for random effects covariates Z i and select the model based on the Deviance Information Criterion (DIC) (33) . The DIC has the advantage of being easy to compute using output from a Gibbs sampler and has a similar form as the Akaika information criterion (AIC): a goodness-of-fit term measured by deviance evaluated at the posterior mean of the parameters, and a penalty term defined by twice of the effective number of parameters. The effective number of parameters is computed as the mean deviance minus the deviance evaluated at the posterior mean. That is,
where Ω is the posterior mean of parameter Ω, p D = dev − dev(Ω) and dev is the posterior mean of the deviance (the average of the deviances calculated using the estimated parameters at each step of the Markov chain Monte Carlo sampler). Based on the form of the DIC, it is obvious that the smaller the DIC value, the better the model proposed. We note that there are several versions of DIC for missing data models (2; 3). Here we use the DIC constructed from the conditional distribution while treating both Ω and W as parameters because it is easy to compute. We conduct a small simulation to evaluate the DIC which selects 147 times out of 200 datasets and the effective dimension is always positive. A cause-specific competing risks sub-model is applied to model diseaserelated dropout (risk 1) and treatment failure or death (risk 2):
The latent variables from both sub-models are assumed to have a multivariate normal distribution with mean zero and variance-covariance matrices
We test the homogeneous random effects covariance matrix assumption by considering subject-dependent covariates for a ijl and b ij . Specifically, we choose a ijl = b ij = (1, CY C i ), which allows heterogeneous covariance matrices for different treatment group, and test the null hypothesis by examining if the 95% credible interval of CYC effects contains zero for all the GARP and IV parameters. A 3-step baseline hazard function, with the time points defining the steps being equally-split percentiles of the observed event times, is utilized for the informatively censored events and the event of treatment failure or death. Sensitivity analyses with 4-and 5-step baseline hazard functions are conducted and show no significant difference. We apply independent noninformative prior distributions for all the parameters which all assumed to have relatively large variances. The corresponding priors for the parameters are Table 1 summarizes the covariance matrix parameters of different models, each was based on 30,000 iterations of MCMC sampling chains following a 15,000-iteration "burn-in" period. Since we include baseline %FVC as a fixed effect covariate, we do not consider random intercept to avoid possible confounding effects. We consider a one-random-slope (before 18 months) model, a structured two-random-slope model assuming the entries of last row in matrix M i from the decomposition are the same, and an unstructured two-random-slope model. The structured random effects covariance matrix model might be useful when dealing with high-dimensional random effects model but with limited data. For the last element of the innovation variance parameter, we do not include the CYC effects due to the convergence issue. It is clear that none of the 95% credible intervals for CYC exclude zero. Therefore, we don't have sufficient evidence to reject the homogeneous random effects covariances assumption. The two-random-slope model with unstructured covariance matrix has the smallest DIC, indicating that it might provide the best fit for the SLS data. Combining the earlier results, we chose the homogenous two-random-slope model with unstructured covariance matrix as our final model and its covariance parameters and DIC values are listed in the last column of Table 1 .
The results of the selected two-random-slope model are summarized in Table 2 . For comparison purposes, we perform separate analysis of the two endpoints, which is done by fitting a linear mixed model with two random slopes (11) for %FVC and a cause-specific hazards frailty model for the competing risks failure time data (13) , (14), respectively. The two methods produce similar point estimates and credible intervals for baseline %FVC, lung fibrosis and their interactions with CYC, but give different results on the interactions of CYC and time trends. With the joint model, the significance of the interactions between CYC and time trends indicates that the developing trends of %FVC in the two groups are different. The %FVC declines for the placebo group (β 4 = −0.12) but increases for the CYC group (β 4 + β 8 = 0.14) in the first 18 months. After 18 months the %FVC declines for the CYC group (β 4 + β 5 + β 8 + β 9 = −0.45) since the CYC effects decrease gradually after the treatment stops, while a positive slope is found for the placebo group (β 4 + β 5 = 0.15). However, none of the time trends is significantly different from zero. The difference might be explained by the significant covariances Σ U 1v and Σ U 2v between the random slopes in the longitudinal model and the latent variable of the survival model, which indicates dependence between the longitudinal measurement %FVC and the survival process. We also observe significantly positive coefficient ν 2 which shows that there is a latent association between the two competing risks. The negative sign of Σ U 1v and positive sign of Σ U 2v together with positive ν 2 indicate that in the first 18 months, there tends to be a lower risk for both treatment failure or death and informatively censored events due to dropout for patients with higher than average increasing rate of %FVC over time; after 18 months, the trend is reversed due to the negative association between the two slopes. The consequence of such informative dropout process results in biased estimates in time trends and attenuated slope changes comparing the CYC group with the placebo group for the separate analysis. The results are confirmed by the simulation study in the later section. The overall effects of treatment CYC on %FVC scores are evaluated by testing the null hypothesis H 0 : β 3 = β 6 = β 7 = β 8 = β 9 = 0 which yields a p-value 0.01 for the joint model and 0.03 for the separate model.
When modeling the competing risks survival data, the two methods produce similar point estimates and CIs for most parameters and identify the same set of significant effects. The joint model is able to identify the relationship (ν 2 ) between the two competing risks much better than the separate model since the separate model does not rely on the additional information from the longitudinal endpoints. We note that, in our second simulation study in the next section, the estimates for ν 2 are not reliable under the current sample size and event rates even for the joint model. Hence we would not overinterpret the quantities in this application. However, the simulation also suggests that the bias of ν 2 does not seem to affect the estimation of other parameters in the joint model. No significant overall effects of CYC are identified for the time to treatment failure or death by testing the null hypothesis H 02 : γ 23 = γ 24 = γ 25 = 0 because of the relatively short follow-up period.
Simulation Studies
We carry out two simulation studies to assess the performance of our method. In the first simulation, the data are generated with heterogeneous covariance matrices and we want to show how the parameter estimates and standard errors would be affected if we ignore the heterogeneity. The longitudinal measurements are simulated from the following model:
where t ij = 0, 0.15, 0.3, . . ., 3, is the scheduled visiting time and X 2i ∼ Bernoulli(0.5) is a group indicator. The measurement error ij ∼ N (0, 5). We simulate two competing risks failure times with the following causespecific hazards:
where X 1 ∼ N (2, 1.0), and X 2 are shared with the longitudinal model. We use constant baseline hazards of 0.12 and 0.25 for risk 1 and risk 2 respectively to generate the event time data. The random effects are generated from the multivariate normal distribution with covariance matrices Σ i which are decomposed into the GARPs and IVs modeled with covariates a ijl = b ij = (1, X 2i ). In other words, the covariance matrices were different in the two groups: strong positive correlation in one group and strong negative correlation in the other. The parameters are given in Table 3 . With this setup, the rate of risk 1 is approximately 0.40, the rate of risk 2 is 0.38 and censoring rate is 0.22. Longitudinal responses are missing after the observed or censored event times. The average number of total longitudinal observations is 11.6 per subject. We use N (0, 10 We analyze the simulated data with the joint analysis modeling the covariance matrices with subject-specific covariates (heterogeneous) and the joint analysis modeling the covariance matrices with subject-independent covariates (homogeneous). We compare bias, estimated standard error (the median of estimated standard error), and coverage rate of the 95% credible intervals in Table 3 . The parameters η 1 and η 2 are transformed back to variance-covariance parameters in the table. It is seen that the heterogeneous joint model gives almost unbiased estimates for all the parameters. In contrast, the homogeneous joint analysis leads to large bias in some of the parameter estimates including γ 12 , γ 22 and ν 2 , which indicates that we may obtain biased parameter estimates for the survival endpoint when combining the information of the longitudinal outcome if the correlation of the two endpoints is incorrectly modeled. Therefore, ignoring the heterogeneity can result in biased estimates and invalid inference.
We conduct the second simulation by generating data with structures similar to the scleroderma lung study. The longitudinal measurements and the competing risks event times are simulated from model (11)- (14) with
, where the covariates are generated from distributions close to what we observe in the real data. All the parameters for the joint model are set to the estimated values from the joint analysis for SLS in Table 2 . Weibull distributions are used as the true baseline hazard function which produce similar risk rates and censoring rate to those in SLS. The results of the joint model and the separate analysis are compared in Table 4 using 200 simulated datasets with sample size m = 140. MCMC sampling is run in 10, 000 iterations, and the estimation results were based on the last 5, 000 iterations. It is shown that the joint model produces good point estimates and coverage rates for most of the parameters in the longitudinal sub-model except for the time trend after 18 months (β 5 ) and the corresponding variance (Σ U 22 ). The separate analysis gives biased estimates for both time trends and their corresponding variances. These biases do not decreases even for a large sample size of 500 (simulation results are not reported here) since the biases are the consequences of the informative dropout process, which cannot be accounted for by the linear mixed effects alone. In contrast, the biases in the joint model are much improved with increased sample size. The random effects coefficient ν 2 and frailty σ 2 v and their standard errors are poorly estimated by the separate competing risks models. The joint model gives biased estimate for ν 2 as well, which suggests that with a small sample size 140 and low event rates (10% for risk 1 and 23% for risk 2), even the joint analysis may not provide good estimates for the frailty at the survival endpoint.
Discussion
For simplicity, we assume in our model that the measurement errors are mutually independent and normally distributed with constant variance. This assumption can be weakened and our method can be modified to handle correlated normal random errors. Our model also assumes that the longitudinal sub-model and survival sub-model are independent conditional on the observed data and latent variables. This may not be satisfied in a real study such as the scleroderma lung study, in which one of the risks in the survival endpoint, treatment failure or death, is partly determined by the longitudinal outcome %FVC. We did some sensitivity analyses and found that our model is robust for mild violation of the independence assumption.
Our model can be extended to clustered data. Frequently, clustered data arises from multi-site clinical trials or from studies across families, in which each site or family can be viewed as a cluster. The cluster effect can be conveniently incorporated as a random effect or as design vectors for the GARP/IV parameters to take into account the heterogeneity across the cluster. Similarly, our method can be extended to recurrent event data where each subject may repeatedly experience a certain phenomenon. In addition, within our joint model framework, the linear mixed sub-model can be extended to the generalized linear mixed effects model (10) to handle nonnormally distributed data, such as binomial or Poisson outcomes. Due to the complexity of the likelihood function in both GLMMs and joint models, only a few papers discussed such a generalized joint model framework (26; 13; 22; 39) . Although in our joint model the posterior sampling distributions for the fixed and random effects in the longitudinal sub-model need to be changed, the parameters in the survival sub-model and the joint variancecovariances parameters can be sampled with our described algorithm. One of the possible approaches to sample the parameters in the GLMM sub-model is to update the fixed and random effects by constructing a normal proposal distribution with mean and variance from a single iteration of weighted least squares based on the previous value (15) .
We finally note that the modified Cholesky decomposition can provide an unconstrained and statistically meaningful reparameterization of a covariance matrix, but at the expense of imposing an order among the underlying random variables. Despite of this shortcoming, it has been used effectively in various applications including multivariate quality control, multivariate time series, finance and random effects models (28) .
APPENDIX
This section provides details for the full conditional distributions of the parameters used in the Gibbs sampling algorithm. We use p(.) and p(.|.) to denote marginal and conditional densities, respectively. We denote the prior distribution by p 0 (.). Based on the modified Cholesky decomposition, the random effects v i can be written as
3. Sample the random effects U i from
i is a q × q matrix consisting of the first q columns and rows of M i , H * i is a q × q matrix consisting of the first q columns and rows of H i . We use the one-step Metropolis-Hastings algorithm to obtain the update in the sampling sequence with the normal density from the longitudinal data as the proposal density. The random effects U i is obtained by first sampling a random variable form the conditional density based on the longitudinal data and then using the conditional likelihood contribution from the survival data to determine the acceptance of the new draw.
where Q i is a q × q 1 matrix with first row Q i1 = 0 and j
. . , q. We sample η 1 in two steps: sample the entries only involves U i from the normal conditional density, sample the entries involves U i and v i with adaptive rejection sampling.
Sample η
We use a Metropolis-Hastings step with a normal approximation to the full conditional as the candidate distribution. For details, see (6).
We use a Metropolis-Hastings step within the single component sampler to update the values of these parameters. For each of these parameters, we propose a normal density as the proposal density, which has the current value of the parameter as its mean and its standard deviation is set equal to four times the standard error of a maximum partial likelihood estimate from a standard Cox model (36).
7. Sample ν k with ARS from
The sample is obtained by first sampling a candidate from the normal densities as its assumption and then using the conditional likelihood contribution from the survival data to determine the acceptance of the new draw.
9. Sample each piece of λ 0k (k = 1, . . . , g) from
k ) + 1 indicates the number of events occurring in the time interval (t 
